Isomorphic Labs, the drug-discovery company spun out of Google DeepMind, said Tuesday it has raised $5 billion in a Series C round led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining as a new investor. The round comes just six months after the company's $2.1 billion Series B, underscoring how quickly capital has flowed toward AI-driven biotech even as broader markets have turned choppy.
Earlier backers, including Thrive Capital and Alphabet's venture arms GV and CapitalG, also participated in the new round, which brings Isomorphic's total outside funding to roughly $7.7 billion since its 2021 spinout from DeepMind. The company, led by DeepMind co-founder Sir Demis Hassabis, has not disclosed a formal valuation for the round, though Fierce Biotech's coverage of the raise notes Bloomberg had reported the company was seeking a valuation near $50 billion.
From protein folding to the clinic
Isomorphic uses AI models descended from DeepMind's AlphaFold protein-structure work to design small-molecule drug candidates, and has discovery partnerships with Novartis, Eli Lilly and Johnson & Johnson. Unlike many AI-in-biotech startups that license their models to pharmaceutical partners and stop there, Isomorphic has also been building its own internal drug pipeline, and the company says the new funding is earmarked specifically for moving its first wholly owned candidates into human clinical trials.
That shift — from a platform company to one that also owns its own drug candidates — is a more capital-intensive and higher-risk path than pure software licensing, since clinical trials can run hundreds of millions of dollars per program with no guarantee of success. Investors backing the round are, in effect, betting that Isomorphic's AI-generated molecules will clear the same clinical hurdles that sink the vast majority of conventionally discovered drug candidates, at a fraction of the traditional discovery timeline.
The raise lands at a moment when investors have grown more skeptical of AI valuations generally, following a volatile week on Wall Street driven partly by questions about whether AI infrastructure spending will pay off. Isomorphic's ability to pull in $5 billion anyway suggests that, for now at least, AI-driven drug discovery is being treated as a distinct and still-hot category rather than being lumped in with broader AI jitters.